Fast and innovative CLIA automation for the monitoring of patients treated with Infliximab
Products are for professional/laboratory use only.
Abacus dx are pleased to present this poster from Theradiag on the performance of the new and innovative i-Tracker infliximab and anti-infliximab assays for use in Therapeutic Drug Monitoring (TDM) on a fully automated, random access, chemiluminescence (CLIA) platform.
Development and evaluation of i-Tracker infliximab and i-Tracker anti-infliximab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with infliximab.
The study concluded:
i-Tracker infliximab and i-Tracker anti-infliximab kits are innovative assays which exhibit fast, accurate, and reproducible results. Excellent agreement was observed with LISA TRACKER assays. i-Tracker kits are valuable tools for the monitoring of patients treated with infliximab (primary drug and biosimilars) and allows for rapid treatment adjustment.
Theradiag i-Tracker Infliximab and Anti-Infliximab:
- Standardised according to the NISBC/WHO Infliximab Standard (#16/170)
- First results in less than 35 minutes
- i-Tracker measurement range: Infliximab: 0.3-24μg/ml; anti-infliximab: 10-2000ng/mL
- Intra-run precision : High accuracy reached with CV ranged from 1.6% to 8.1% for i-Tracker Infliximab assay and between 1.7% and 11.1% for i-Tracker anti-Infliximab assay
- Inter-run precision: High accuracy reached with CV ranged from 2.0% to 6.7% for i-Tracker infliximab assay and between 2.3% to 4.8% for i-Tracker anti-infliximab assay
- i-Tracker assays are not disrupted by the presence of Biologic agents as bilirubin (2mg/ml), hemoglobin (0,2mg/ml), tryglycerides (33mg/ml), rheumatoid factors (1000 AU/ml) and biotin (2μg/ml)
- Excellent correlation observed with LISA TRACKER assays.
Abacus dx offer Theradiag i-Tracker with full automation on the IDS iSYS CLIA platform – the first fully automated, random access technology with unparalleled turn-around times for TDM.
